• 1. An alumina stabilized graphene oxide wrapped SnO2 hollow sphere LIB anode with improved lithium storage?
  Xiang Liu,Qian Sun,A. B. Djuri?i?,Maohai Xie,Baohu Dai,Jinyao Tang,Charles Surya,Changzhong Liao,Kaimin Shih RSC Adv., 2015,5, 100783-100789
• 2. An artificial CO-releasing metalloprotein built by histidine-selective metallation?
  Inês S. Albuquerque,Hélia F. Jeremias,Miguel Chaves-Ferreira,Dijana Matak-Vinkovic,Omar Boutureira,Carlos C. Rom?o Chem. Commun., 2015,51, 3993-3996
• 3. An artificial photosynthesis system comprising a covalent triazine framework as an electron relay facilitator for photochemical carbon dioxide reduction?
  Siquan Zhang,Shengyao Wang,Liping Guo,Hao Chen,Bien Tan,Shangbin Jin J. Mater. Chem. C, 2020,8, 192-200
• 4. An astrophysically-relevant mechanism for amino acid enantiomer enrichment
  Stephen P. Fletcher,Richard B. C. Jagt,Ben L. Feringa Chem. Commun., 2007, 2578-2580
• 5. An intermolecular C–C coupling reaction of iridium complexes?
  Kathrin Kutlescha,Rhett Kempe New J. Chem., 2010,34, 1954-1960

• Solvents and Organic Chemicals Organic Compounds Organic acids and derivatives Carboxylic acids and derivatives Amino acids, peptides, and analogues Amino acids and derivatives

Introduction to Tert-Butyl 2-(3-amino-5-methyl-1H-pyrazol-1-yl)acetate (CAS No. 1946813-49-5)

Tert-Butyl 2-(3-amino-5-methyl-1H-pyrazol-1-yl)acetate, with the chemical formula C₉H₁₃N₃O₂, is a significant compound in the field of pharmaceutical research and development. This compound, identified by its CAS number 1946813-49-5, has garnered attention due to its potential applications in medicinal chemistry and drug design. The structure of this molecule incorporates a pyrazole core, which is a well-known scaffold in the development of bioactive molecules.

The pyrazole moiety in Tert-butyl 2-(3-amino-5-methyl-1H-pyrazol-1-yl)acetate plays a crucial role in its pharmacological properties. Pyrazoles are heterocyclic compounds that exhibit a wide range of biological activities, including anti-inflammatory, antimicrobial, and antiviral effects. The presence of an amino group at the 3-position and a methyl group at the 5-position further enhances the compound's potential as a pharmacophore. These substituents can interact with biological targets, making the compound a valuable candidate for further investigation.

In recent years, there has been growing interest in developing novel therapeutic agents based on pyrazole derivatives. The compound Tert-butyl 2-(3-amino-5-methyl-1H-pyrazol-1-yl)acetate has been studied for its potential role in modulating various biological pathways. For instance, research has suggested that this compound may have inhibitory effects on certain enzymes and receptors involved in inflammation and pain signaling. These findings make it an attractive candidate for the development of new drugs targeting chronic inflammatory diseases.

The tert-butyl group attached to the acetate moiety in the molecule contributes to its stability and solubility characteristics. This is particularly important in pharmaceutical applications where the physicochemical properties of a drug can significantly impact its efficacy and bioavailability. The stability of Tert-butyl 2-(3-amino-5-methyl-1H-pyrazol-1-yl)acetate under various conditions makes it suitable for further chemical modifications and derivatization, allowing researchers to explore its full pharmacological potential.

Recent advancements in computational chemistry have enabled more efficient screening of compounds like Tert-butyl 2-(3-amino-5-methyl-1H-pyrazol-1-yl)acetate for their biological activity. Molecular docking studies have been used to predict how this compound might interact with target proteins. These studies have shown promising results, indicating that the compound could bind effectively to several key targets relevant to inflammation and pain management. Such insights are invaluable for guiding experimental efforts and optimizing lead compounds for clinical development.

The synthesis of Tert-butyl 2-(3-amino-5-methyl-1H-pyrazol-1-yl)acetate involves multi-step organic reactions that require careful optimization to ensure high yield and purity. Researchers have developed synthetic routes that leverage modern techniques such as palladium-catalyzed cross-coupling reactions, which enhance efficiency and minimize byproduct formation. These synthetic strategies are crucial for producing sufficient quantities of the compound for both preclinical studies and potential future clinical trials.

The pharmacokinetic properties of Tert-butyl 2-(3-amino-5-methyl-1H-pyrazol-1-yl)acetate are also subjects of interest. Studies have begun to investigate how the compound is absorbed, distributed, metabolized, and excreted by the body. Understanding these processes is essential for determining appropriate dosing regimens and predicting potential side effects. Preliminary data suggest that the compound exhibits favorable pharmacokinetic profiles, which could make it suitable for oral administration and repeated dosing.

In conclusion, Tert-butyl 2-(3-amino-5-methyl-1H-pyrazol-1-yl)acetate (CAS No. 1946813-49-5) represents a promising area of research in pharmaceutical chemistry. Its unique structure, incorporating a pyrazole core with specific substituents, positions it as a valuable candidate for further exploration in drug development. With ongoing studies focusing on its biological activity, synthetic pathways, and pharmacokinetic properties, this compound holds significant potential for addressing various therapeutic challenges.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)